TITLE

Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients

AUTHOR(S)
Naito, Takafumi; Tashiro, Masaki; Yamamoto, Keisuke; Ohnishi, Kazunori; Kagawa, Yoshiyuki; Kawakami, Junichi
PUB. DATE
October 2012
SOURCE
European Journal of Clinical Pharmacology;Oct2012, Vol. 68 Issue 10, p1411
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: Cancer cachexia is characterized by hypoalbuminemia and with the hepatic production of acute-phase proteins in response to malignant growth. The aim of this study was to evaluate the influence of cachexia on the pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients. Methods: Forty-seven Japanese patients receiving oxycodone extended-release tablets as a starting opioid for cancer pain were enrolled in this study. Cachexia was evaluated using the Glasgow Prognostic Score (GPS). Predose plasma concentrations of oxycodone and noroxycodone were determined at the titration dose. Results: Seven patients had a GPS of 0, 21 a GPS of 1, and 19 had a GPS of 2. A higher GPS was significantly correlated with a higher oxycodone concentration and a lower concentration ratio of noroxycodone to oxycodone and significantly associated with a lower incidence of dose escalation and a higher incidence of central adverse reactions. Serum albumin, but not α-acid glycoprotein and C-reactive protein, was inversely correlated with the free fraction of oxycodone. Serum albumin concentration was significantly associated with the incidence of dose escalation. In contrast, the free fraction of oxycodone and acute-phase proteins were not related to the clinical responses. Conclusions: Cachexia had an effect on oxycodone metabolism and the clinical responses to oxycodone. The observed reduction in serum albumin concentration was associated with dose escalation. These findings suggest that cachexia affects the clinical responses to oxycodone through metabolic and nutritional disorders in cancer patients.
ACCESSION #
79824366

 

Related Articles

  • Biology of Cachexia. Tisdale, Michael J. // JNCI: Journal of the National Cancer Institute;12/03/97, Vol. 89 Issue 23, p1763 

    Focuses on the syndrome of cachexia in cancer patients. Relationship between anorexia and cachexia; Metabolism in cancer cachexia; Factors implicated in cancer cachexia; Treatment of cancer cachexia.

  • New strategies to overcome cancer cachexia: from molecular mechanisms to the 'Parallel Pathway.'. Muscaritoli, Maurizio; Costelli, Paola; Aversa, Zaira; Bonetto, Andrea; Baccino, Francesco Maria; Fanelli, Filippo Rossi // Asia Pacific Journal of Clinical Nutrition;2008 Supplement 1, Vol. 17, p387 

    Cancer has always a negative impact on nutritional status, weight loss being a common feature in patients with neoplastic diseases. If left untreated, weight loss may evolve into cancer cachexia, a complex syndrome characterized by marked depletion of body weight, associated with profound...

  • The Science of Megestrol Acetate Delivery: Potential to Improve Outcomes in Cachexia. Femia, Robert A.; Goyette, Richert E. // BioDrugs;2005, Vol. 19 Issue 3, p179 

    Cachexia, usually defined as the loss of >5% of an individual’s baseline bodyweight over 2–6 months, occurs with a number of diseases that includes not only AIDS and advanced cancer but also chronic heart failure, rheumatoid arthritis, chronic obstructive pulmonary disease, Crohn...

  • Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Andreassen, Trine; Klepstad, Pål; Davies, Andrew; Bjordal, Kristin; Lundström, Staffan; Kaasa, Stein; Dale, Ola // European Journal of Clinical Pharmacology;May2011, Vol. 67 Issue 5, p493 

    Objective: Oxycodone is widely used for the treatment of cancer pain, but little is known of its pharmacokinetics in cancer pain patients. The aim of this study was to explore the relationships between ordinary patient characteristics and serum concentrations of oxycodone and the ratios...

  • Cancer Cachexia: It Takes a Teamto Fix the Complex Machinery. Hui, David // Journal of Oncology Practice;Nov2016, Vol. 12 Issue 11, p1172 

    The author discusses issues concerning the treatment and management of cachexia, one of the most metabolic syndromes in patients with advanced cancer. He explains that cachexia is associated with suboptimal treatment outcomes, increased mortality and decreased physical function. He also explains...

  • Cancer Cachexia: Emerging pre-clinical evidence and the pathway forward to clinical trials. Martin, Lisa; Sawyer, Michael B. // JNCI: Journal of the National Cancer Institute;Dec2015, Vol. 107 Issue 12, p1 

    The authors present insights on the emerging preclinical evidence and the pathway forward to clinical trials on cancer cachexia. Topics discussed include cachexia as an unment medical need in oncology due to its devastating effects on patients, the complexity of cachexia treatment, and targets...

  • Parenteral Nutrition in Advanced Cancer: Indications and Clinical Practice Guidelines. Mirhosseini, Noush; Fainsinger, Robin L.; Baracos, Vickie // Journal of Palliative Medicine;Oct2005, Vol. 8 Issue 5, p914 

    Cachexia is a disturbing and disfiguring aspect of many advanced cancers. Parenteral nutrition (PN) is a controversial and expensive treatment for cancer cachexia. Guidelines for the use of PN for these patients have been suggested. These two case reports will highlight some of the issues around...

  • Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients. Fujiwara, Yutaka; Toyoda, Masanori; Chayahara, Naoko; Kiyota, Naomi; Shimada, Takanobu; Imamura, Yoshinori; Mukohara, Toru; Minami, Hironobu // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Purpose: Oxycodone is a µ-opioid receptor agonist widely used in the treatment of cancer pain. The predominant metabolic pathway of oxycodone is CYP3A4-mediated N-demethylation to noroxycodone, while a minor proportion undergoes 3-O-demethylation to oxymorphone by CYP2D6. The aim of this...

  • Symptom Control in Palliative Care–Part II: Cachexia/Anorexia and Fatigue. Del Fabbro, Egidio; Dalal, Shalini; Bruera, Eduardo; Arnold, Robert M.; Liao, Solomon // Journal of Palliative Medicine;Apr2006, Vol. 9 Issue 2, p409 

    Provides information on palliative care and symptom control of cachexia, anorexia, and fatigue manifested by patient with cancer. Mechanism of cachexia, anorexia, and fatigue; Assessment and clinical management; Pharmacologic and nonpharmacologic approaches.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics